Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 93 full-time employees. The firm has filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code. The firm remains in possession of its assets and continues to operate its business as a debtor in possession.

Industry: Biological Products, (No Diagnostic Substances) Peers: Aldeyra Therapeutics Inc ALPINE IMMUNE SCIENCES, INC. MiMedx Group Inc Annexon Inc Arbutus Biopharma Corp Tango Therapeutics Inc Biomea Fusion Inc CONCERT PHARMACEUTICALS, INC. Tyra Biosciences Inc